Company intelligence / Profile preview

Lophora

Ownership: Private
Employees: ~10
Development stage: Phase 1

Overview

Lead compound LPH-5 has entered Phase I trials after showing robust CNS exposure, target engagement, and efficacy in animal models of depression. The company received approval from the European Medicines Agency (EMA) to commence Phase I clinical study for LPH-5 and completed a $3 million financing round to support this phase[2][4].

Therapeutic areas: Psychiatry
Modalities: Small moleculespsychedelic compounds
Industry: Biotech

Drug pipeline

4 assets

LPH-5

3 more assets in the full pipeline.

Beyond the preview

Go deeper on Lophora.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lophora.